Veru announces selection of novel modified release oral enobosarm formulation for chronic weight loss management following pharmacokinetic clinical study

Miami, aug. 11, 2025 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced selection of a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator, for chronic weight loss management, following confirmation of pharmacokinetic endpoints in a clinical study.
VERU Ratings Summary
VERU Quant Ranking